<span item_type="fundamental" item_id="fa1789cfaceeef406ef03f5b8be9680b" counter_id="ST/US/WGSWW" env="prod"></span><span item_type="announcement" item_id="576479454845470721" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 116.74 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.27.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.689 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenue for the third quarter of 2025 was $116.7 million, a 52% increase year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li><li>Exome and genome test revenue was $98.9 million, representing a 65% increase year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Adjusted gross margin expanded to 74%, up from 64% in the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li><li>Adjusted net income was $14.7 million, compared to $2.0 million in the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span></li><li>GAAP net loss was - $7.6 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span></li><li>Adjusted total operating expenses for Q3 2025 were $71 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Free cash flow for the third quarter of 2025 was $8.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span></li><li>Cash, cash equivalents, marketable securities, and restricted cash totaled $156.1 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Exome and genome test volume grew to 25,702, a 33% increase year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span></li><li>Exome and genome tests accounted for 43% of all tests, up from 33% in the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>GeneDx raised its full-year 2025 revenue guidance to between $425 and $428 million, with expected growth in exome and genome revenue between 53% to 55%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li><li>The company anticipates an adjusted gross margin of 70% to 71% and positive adjusted net income each quarter and for the full year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025pressrelease.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/q32025earningspresentati.htm"></span></li></ul>

GeneDx - CW27 | 8-K: FY2025 Q3 Revenue: USD 116.74 M